Recreational substance use and tolerance of efavirenz in HIV-1 infected patients

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 17, Issue 7, 2005, Pages 908-910

  Faggian, F ^a   Lattuada, E ^a   Lanzafame, Massimiliano ^a   Antolini, D ^a   Concia, E ^a   Vento, S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; COCAINE; EFAVIRENZ; RECREATIONAL DRUG;

ADULT; AGED; AMNESIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONCENTRATION LOSS; DREAM; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; EROTISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NIGHTMARE; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS;

EID: 24644469195     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540120500038371     Document Type: Article

References (8)

1. Bristol-Myers Squibb Company (2002). Sustiva product information. Princeton, NJ: Bristol-Meyers Squibb Company.
2. Carr, A. (2004). Antiretroviral therapy for previously untreated HIV-1 infected adults: 2NN, or just one? Lancet, 363, 1248-1250.
3. Harrington, R.D., et al. (1999). Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Archives of Internal Medicine, 159, 2221-2224.
4. Henry, J.A., & Hill, I.R. (1998). Fatal interaction between ritonavir and MDMA. Lancet, 352, 1751-1752.
5. Hirscel, B., et al. (2002). Switching from protease inhibitors to efavirenz: Differences in efficacy and tolerability among risk groups. A case control study from the Swiss HIV cohort. AIDS, 16, 381-385.
6. Montaner, J.S.G., et al. (2002). FOCUS study: Saquinavir QD regimen versus efavirenz QD regimen 48-week analysis in HIV infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September, San Diego.
7. Perez-Molina, J.A. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-infected patients. HIV Clinical Trials, 3, 279-286.
8. Staszewski, S., et al. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-infection in adults. New England Journal of Medicine, 341, 1865-1873.